GrandeLASH-MD vs RevitaLash:Which Is Safer in 2026?
Neither is recommended based on current regulatory science. GrandeLASH-MD contains isopropyl cloprostenate (ICP) and RevitaLash Advanced contains dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE) — both prostaglandin analogues ruled "cannot be considered safe" by the EU SCCS in February 2026 (SCCS/1680/25). If you must pick one: GrandeLASH-MD is cheaper per mL and claims faster results; RevitaLash has more clinical heritage. But the genuinely safe upgrade from either is a prostaglandin-free serum with independent clinical data — like Toplash, which delivers +52.3% lash length in 8 weeks without any PGA.
Updated: June 20, 2026 Written by: Branda M. Heim Reviewed by: Branda M. Heim, Board-Certified CosmetologistView Toplash SerumNeither is recommended based on current regulatory science. GrandeLASH-MD contains isopropyl cloprostenate (ICP) and RevitaLash Advanced contains dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE) — both prostaglandin analogues ruled "cannot be considered safe" by the EU SCCS in February 2026 (SCCS/1680/25). If you must pick one: GrandeLASH-MD is cheaper per mL and claims faster results; RevitaLash has more clinical heritage. But the genuinely safe upgrade from either is a prostaglandin-free serum with independent clinical data — like Toplash, which delivers +52.3% lash length in 8 weeks without any PGA.
The EU Scientific Committee on Consumer Safety ruled that ICP (GrandeLASH-MD) and DDDE (RevitaLash Advanced) both "cannot be considered safe" for cosmetic use near the eye area. This applies to all cosmetic lash serums containing either prostaglandin analogue, regardless of brand or concentration.
At a Glance
Grande Cosmetics
GrandeLASH-MD Lash Enhancing Serum
- Prostaglandin analogue: ICP (Isopropyl Cloprostenate)
- EU SCCS safe: ✗ ICP ruled unsafe
- Claimed results: ~35% fullness at 12 wks
- Visible change: 4–6 weeks (brand)
- Price / mL: ~$32.50/mL
Revitalash Inc.
RevitaLash Advanced Eyelash Conditioner
- Prostaglandin analogue: DDDE (Ethylcloprostenolamide)
- EU SCCS safe: ✗ DDDE ruled unsafe
- Claimed results: 20–30% at 16 wks
- Visible change: 8–12 weeks (brand)
- Price / mL: ~$32.50–$35/mL
Head-to-Head Comparison
Both products carry the same core safety concern — a prostaglandin analogue now ruled unsafe by EU regulators. Below are the meaningful differences between them.
| Factor | GrandeLASH-MD | RevitaLash Advanced |
|---|---|---|
| Prostaglandin-free | ✗ ICP present | ✗ DDDE present |
| EU SCCS (Feb 2026) compliant | ✗ ICP not safe | ✗ DDDE not safe |
| Prostaglandin analogue name | Isopropyl Cloprostenate (ICP) | DDDE (Ethylcloprostenolamide) |
| Supporting complex | Peptides, HA, botanicals | BioPeptin Complex, green tea, biotin |
| Claimed results timeline | 4–6 weeks (faster) | 8–12 weeks |
| Brand clinical claim | ~35% fullness at 12 wks | 20–30% at 16 wks |
| Independent clinical trial? | ✗ Brand commissioned | Ophthalmologist supervised |
| Clinical heritage | Newer brand | Founded by ophthalmologist (2006) |
| Standard size | 2 mL | 2 mL / 3.5 mL |
| Price per mL | ~$32.50/mL | ~$32.50–$35/mL (higher) |
| Iris color change risk | ✗ ICP risk | ✗ DDDE risk |
| Periorbital fat loss risk | ✗ ICP risk | ✗ DDDE risk |
| Class action lawsuit? | No | ⚠ Filed (undisclosed side effects) |
| Ophthalmologist tested | ✓ (marketing claim) | ✓ (ophthalmologist-founded) |
Ingredients Breakdown
While the two serums differ in supporting actives and brand positioning, the central issue is the same: both use a prostaglandin analogue as their primary growth driver.
GrandeLASH-MD
ICP + Peptide Complex
- Isopropyl Cloprostenate (ICP) ⚠ EU: Not Safe — primary growth active; prostaglandin analogue ruled unsafe by EU SCCS February 2026.
- Hyaluronic acid — follicle zone hydration; supports moisture balance at the lash line.
- Peptide blend — conditioning support; not a standalone growth mechanism without ICP.
- Grape seed extract — antioxidant; protective against free radical damage at the follicle.
- Aloe vera / chamomile — soothing botanicals to reduce irritation from ICP application.
RevitaLash Advanced
DDDE + BioPeptin Complex
- DDDE (Dechloro Dihydroxy Difluoro Ethylcloprostenolamide) ⚠ EU: Not Safe — primary growth active; prostaglandin analogue. Replaced bimatoprost in 2007 following FDA action. Also ruled unsafe by EU SCCS February 2026.
- BioPeptin Complex — proprietary peptide blend (including sh-Oligopeptide-1); supports lash conditioning alongside DDDE.
- Green tea extract (EGCG) — antioxidant protection; may support follicle environment.
- Biotin — maintains lash appearance; limited topical absorption evidence.
- Panthenol (B5) — coats and strengthens lash fibres.
Safety Profile: Two PGAs, Same Risks
Despite being chemically distinct, ICP and DDDE produce a nearly identical risk profile because they act through the same prostaglandin receptor pathway.
The SCCS evaluated ICP (GrandeLASH-MD), DDDE (RevitaLash Advanced), and MDN together: "None of the three prostaglandin analogues can be considered safe for use in cosmetic products intended for promoting the growth of eyelashes and eyebrows." The ruling is based on their potent pharmacological activity even at low concentrations and the absence of data sufficient to rule out reproductive or developmental toxicity.
Clinical Data Comparison
Both brands report positive results, but there are meaningful differences in the type of evidence, how results are measured, and the timeline to visible improvement.
GrandeLASH-MD
- Lash fullness claim: ~35%
- Lash length claim: ~25%
- Timeline: 12 weeks
- Evidence type: Brand-commissioned
- First visible change: 4–6 weeks
RevitaLash Advanced
- Lash improvement claim: 20–30%
- Lash length claim: Varies by study
- Timeline: 16 weeks
- Evidence type: Ophthalmologist supervised
- First visible change: 8–12 weeks
Toplash (PGA-Free Comparison)
- Lash length increase: +52.3%
- Lash volume increase: +31.9%
- Timeline: 8 weeks
- Evidence type: ✓ Independent clinical trial
- First visible change: Day 21 (98% of users)
✓ No prostaglandins. +52.3% length is independently measured — not brand-commissioned. EU SCCS compliant.
Pricing Comparison
Both PGA-containing serums are significantly more expensive per mL than Toplash — and come with EU safety concerns attached.
GrandeLASH-MD
$65 for 2 mL
$32.50 / mL
RevitaLash Advanced
$65–$70 for 2 mL
~$33–$35 / mL
Toplash (PGA-Free)
$49.90 for 3 mL (larger bottle)
$16.63 / mL ✓
Per-mL comparison: Both GrandeLASH-MD (~$32.50/mL) and RevitaLash (~$33–35/mL) cost roughly twice as much per mL as Toplash ($16.63/mL) — while also containing prostaglandin analogues now ruled unsafe by EU regulators. Toplash is the lower-cost option that also happens to be the safer one.
Verdict: The Better Answer Is Neither
Skip the PGA Debate — Choose the Safe Option
GrandeLASH-MD and RevitaLash are both effective — but both rely on prostaglandin analogues now classified as unsafe by EU regulators. If you're choosing between them for price, GrandeLASH-MD is slightly cheaper per mL and may show faster initial results. If heritage and ophthalmologist origin matter, RevitaLash has the longer track record. But neither choice is safe by 2026 regulatory standards.
Toplash resolves the dilemma: a prostaglandin-free triple-peptide serum with independently verified +52.3% lash length in 8 weeks, EU SCCS compliance, and a price per mL nearly half that of either competitor.
Try Toplash PGA-Free — $49.90Frequently Asked Questions
Which is better — GrandeLASH-MD or RevitaLash Advanced?
If forced to choose: GrandeLASH-MD offers slightly faster claimed results (4–6 weeks) at a lower price per mL. RevitaLash has more established clinical heritage and was founded by an ophthalmologist. However, both contain prostaglandin analogues ruled "cannot be considered safe" by the EU SCCS in February 2026. Neither is recommended for long-term use. A prostaglandin-free alternative with independent clinical data — like Toplash — is the better choice for sustained lash health.
Does RevitaLash contain prostaglandins?
Yes. RevitaLash Advanced contains DDDE (dechloro dihydroxy difluoro ethylcloprostenolamide) — a synthetic prostaglandin analogue. RevitaLash reformulated from bimatoprost (a drug-grade PGA) to DDDE in 2007. The current DDDE formula was also ruled "cannot be considered safe" by the EU SCCS in February 2026 (SCCS/1680/25). RevitaLash marketing sometimes states it doesn't contain bimatoprost — which is true, but DDDE is equally flagged by regulators.
Does GrandeLASH-MD contain prostaglandins?
Yes. GrandeLASH-MD contains isopropyl cloprostenate (ICP), a synthetic prostaglandin analogue. ICP was ruled "cannot be considered safe" for cosmetic use near the eyes by the EU SCCS in its final opinion of February 2, 2026 (SCCS/1680/25). Known risks include iris color change, periorbital fat loss, skin hyperpigmentation, and rebound shedding when discontinued.
What is the difference between ICP (GrandeLASH) and DDDE (RevitaLash)?
Both ICP and DDDE are synthetic prostaglandin analogues that extend the eyelash anagen (growth) phase by binding to prostaglandin receptors in the hair follicle. They share a nearly identical risk profile: iris color change, orbital fat loss, lid hyperpigmentation, and rebound shedding. The EU SCCS evaluated both compounds in the same 2026 opinion and reached the same conclusion for both — "cannot be considered safe" for cosmetic use near the eye area.
Which shows faster results — GrandeLASH-MD or RevitaLash?
GrandeLASH-MD claims faster visible results — 4–6 weeks vs RevitaLash's 8–12 weeks — and a higher percentage improvement in a shorter timeframe (35% at 12 weeks vs 20–30% at 16 weeks). Both figures are from brand-commissioned studies. For context, Toplash (prostaglandin-free) shows +52.3% length at just 8 weeks in independent clinical testing, and 98% of users notice visible change by day 21.
Is there a safer alternative to both GrandeLASH-MD and RevitaLash?
Yes. Toplash is a prostaglandin-free triple-peptide lash serum (MP-17, BTP-1, AT-3) with independently verified +52.3% lash length and +31.9% volume in 8 weeks. It contains no prostaglandin analogues of any kind, is fully EU SCCS compliant, and is ophthalmologist-tested. At $49.90 for 3 mL ($16.63/mL), it also costs roughly half the per-mL price of either GrandeLASH-MD or RevitaLash Advanced.
Can I switch from GrandeLASH-MD or RevitaLash to a PGA-free serum?
Yes. You can switch directly from either product to a prostaglandin-free serum like Toplash without a waiting period. Expect a brief adjustment phase as the lash cycle resets from its artificially extended PGA-driven state — some users notice increased shedding before baseline is re-established. Applying Toplash daily through this transition supports follicle health with its peptide complex. Allow 12 weeks for full results to establish after making the switch.